Table 3.
MTV and TLG measurements of CRC patients.
| MTV with fixed threshold method | MTV with percent threshold method | |||||||
|---|---|---|---|---|---|---|---|---|
| 2.5 | 3.0 | 4.0 | 5.0 | 30% | 40% | 50% | 60% | |
| MSI | 72.0 (41.93,80.8) | 62.97 (33.29,70.65) | 50.92 (24.13,57.83) | 41.60 (18.52,49.96) | 38.24 (23.27,48.34) | 27.38 (14.65,33.86) | 17.40 (10.19,24.12) | 10.16 (6.46,16.78) |
| MSS | 40.21 (23.14,78.87) | 34.12 (19.54,70.73) | 25.83 (14.73,59.71) | 20.37 (11.64,43.42) | 17.90 (12.0,36.89) | 11.79 (8.59,22.87) | 7.49 (4.94,13.51) | 4.45 (2.76,7.93) |
| p-value | 0.087 | 0.101 | 0.182 | 0.158 | 0.005 | 0.002 | 0.001 | 0.002 |
| TLG with fixed threshold method | TLG with percent threshold method | |||||||
| 2.5 | 3.0 | 4.0 | 5.0 | 30% | 40% | 50% | 60% | |
| MSI | 475.16 (209.33,632.36) | 450.89 (209.33,632.36) | 409.11 (178.06,582.65) | 367.12 (156.62,546.46) | 371.17 (185.63,474.80) | 283.05 (137.02,413.55) | 178.77 (106.44,335.98) | 110.23 (69.57,228.48) |
| MSS | 256.12 (136.95,600.94) | 238.44 (129.04,578.47) | 211.22 (114.0,528.22) | 186.83 (100.83,476.36) | 167.66 (105.18,167.66) | 124.57 (86.95,316.87) | 83.31 (68.57,223.38) | 54.92 (43.47,105.0) |
| p-value | 0.208 | 0.226 | 0.208 | 0.208 | 0.091 | 0.07 | 0.028 | 0.022 |
MSI, microsatellite instability; MSS, microsatellite stability; MTV, metabolic tumor volume; TLG, total lesion glycolysis.